Generic Nucynta ER Availability
Last updated on Apr 10, 2024.
See also: Generic Nucynta
Nucynta ER is a brand name of tapentadol, approved by the FDA in the following formulation(s):
NUCYNTA ER (tapentadol hydrochloride - tablet, extended release;oral)
-
Manufacturer: COLLEGIUM PHARM INC
Approval date: August 25, 2011
Strength(s): EQ 50MG BASE [RLD], EQ 100MG BASE [RLD], EQ 150MG BASE [RLD], EQ 200MG BASE [RLD], EQ 250MG BASE [RLD]
Has a generic version of Nucynta ER been approved?
No. There is currently no therapeutically equivalent version of Nucynta ER available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nucynta ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,344,512
Patent expiration dates:
- April 21, 2028✓
- April 21, 2028✓
- April 21, 2028
-
Patent 7,994,364
Patent expiration dates:
- June 27, 2025✓✓✓
- June 27, 2025✓✓✓
- June 27, 2025
-
Abuse-proofed dosage form
Patent 8,114,383
Issued: February 14, 2012
Inventor(s): Bartholomäus Johannes & Kugelmann Heinrich & Arkenau-Marić Elisabeth
Assignee(s): Gruenenthal GmbHThe present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
Patent expiration dates:
- October 10, 2024✓✓
- October 10, 2024
-
Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Patent 8,536,130
Issued: September 17, 2013
Inventor(s): Christoph Thomas & Friderichs Elmar & Koegel Babette-Yvonne & Meen Murielle
Assignee(s): Gruenenthal GmbHUse of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.
Patent expiration dates:
- September 22, 2028✓
- September 22, 2028
More about Nucynta ER (tapentadol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (81)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
- En español
Patient resources
Professional resources
Other formulations
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.